MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3064% below fair value
$8.46−0.28 (-3.20%)
Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –
MeiraGTx ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
MeiraGTx's ebitda for the twelve months ending Jun 30, 2026 was $196.13M. For fiscal 2025 it was -$93.43M. The highest annual figure on record is -$56.03M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$93.43M | – |
| FY2024 | Dec 31, 2024 | -$151.38M | – |
| FY2023 | Dec 31, 2023 | -$123.33M | – |
| FY2022 | Dec 31, 2022 | -$107.63M | – |
| FY2021 | Dec 31, 2021 | -$64.89M | – |
| FY2020 | Dec 31, 2020 | -$58.38M | – |
| FY2019 | Dec 31, 2019 | -$56.03M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $247.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$37.81M | – |
| Q4 FY2025 | Dec 31, 2025 | $29.59M | – |
| Q3 FY2025 | Sep 30, 2025 | -$42.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$38.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$36.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.69M | – |
| Q1 FY2024 | Mar 31, 2024 | -$43.50M | – |
| Q4 FY2023 | Dec 31, 2023 | -$39.84M | – |
| Q3 FY2023 | Sep 30, 2023 | -$29.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.54M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$38.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.63M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.27M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.37M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.86M | – |
See a number that looks wrong?